-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2635 Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL

Program: Oral and Poster Abstracts
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Lymphoid Leukemias, CLL, Diseases, Lymphoid Malignancies
Sunday, December 12, 2021, 6:00 PM-8:00 PM

Thomas Chatzikonstantinou1*, Lydia Scarfo2*, Christos Demosthenous3, Jana Kotaskova4*, Gloria Iacoboni, MD5*, Evangelia Minga6*, Dimitra Chammou7*, Georgios Karakatsoulis8*, Elisa Albi9*, Miguel Alcoceba10*, Shaimaa El-Ashwah, MD11*, Francesca Bacchiarri, MD12*, Mehreen Ali Khan, MBBS13, Thérèse Aurran, MD14*, Anne Calleja15*, Ramona Cassin, MD16*, Sofia Chatzileontiadou, MD17*, Amy Christian18*, Rainer Claus, MD19*, Rosa Collado20*, Marcos Daniel De Deus Santos21*, Zadie Davis18*, Maria Dimou, MD, PhD22, David Donaldson23*, Gimena Dos Santos24*, Barbara Dreta, MD25*, Maria Efstathopoulou26*, Alicia Enrico, MD27*, Alberto Fresa, MD28*, Sara Galimberti29*, Rocío García-Serra30*, Isabel González-Gascón Y Marín, MD, PhD31*, Alessandro Gozzetti12*, Valerio Guarente, MD32*, Sean Harrop, MBBS33*, Eleftheria Hatzimichael34*, Yair Herishanu, MD35*, Luca Inchiappa15*, Michalis Iskas3*, Ozren Jaksic, MD, PhD36, Susanne R. Janssen, MSc37*, Elzbieta Kalicinska, MD, PhD38*, Volkan Karakus, MD39*, Arnon P. Kater, MD, PhD40, Bonnie Kho, MD41*, Iliana Konstantinou42*, Thomas Longval, MD43*, Maya Koren-Michowitz, MD44,45, Ioannis Kotsianidis, PhD46, Robert J. Kreitman, MD47, Uttam Kumar Nath, MD, DM48, Jorge Labrador49*, Deepesh Lad, MD, DM50, Kamel Laribi, MD51*, Ilana Levy52*, Alberto Lopez-Garcia53*, Juan Marquet Palomanes, MD54*, Stanislava Maslejova, MD55*, Carlota Mayor-Bastida56*, Fatiha Merabet57*, Biljana Mihaljevic58,59*, Ivana Milosevic60*, Fatima Miras61*, Riccardo Moia, MD62*, Marta Morawska, MD63,64*, Almudena Navarro-Bailón65*, David Oscier18, Jacopo Olivieri66*, Tomáš Papajík, MD, CSc, Prof67*, Maria Papaioannou68*, Cheyenne Pierie69*, Anna Puiggros, PhD70*, Gianluigi Reda, MD16*, Gian Matteo Rigolin71*, Rosa Ruchlemer, MD72*, Luana Schiattone9*, Omur Gokmen Sevindik, MD73, Yandong Shen, BMedSc (Hon) PhD74*, Martin Šimkovič, MD, PhD75*, Svetlana Smirnova, MD, PhD76*, Dina Sameh Soliman, MD, PhD, MBBS, MSc77, Martin Špaček78*, Annett Schiwitza79*, Tamar Tadmor, MD80*, Liat Tourjeman81*, Eric Tse, MBBS, PhD, FRCP, FRCPath82, Andrea Visentin, MD PhD83*, Kristina Tomic84*, Michel Van Gelder, MD, PhD85, Theodoros P. Vassilakopoulos86*, Candida Vitale, MD, PhD87*, George Vrachiolias88*, Vojin Vukovic84*, Zhenshu Xu, MD89, Lucrecia Yáñez, MD, PhD90*, Munci Yagci91*, Mohamed A Yassin, MBBS, MSc, CABM, MSC, FACP92, Jana Zuchnicka, MD93*, Maria K. Angelopoulou, MD94*, Darko Antic95*, Bella V. Biderman, PhD96*, Mark Catherwood, PhD97*, Marta Coscia, MD, PhD98*, Antonio Cuneo, MD99,100*, Fatih Demirkan, Prof Dr101, Blanca Espinet, PhD102,103*, Gianluca Gaidano, MD104, Romain Guièze, MD105, Olga Kalashnikova, MD106*, Luca Laurenti, MD107*, Stephen Mulligan108*, Roberta Murru, MD109*, Eugene A. Nikitin, MD, PhD, Prof.110, Panayiotis Panayiotidis, MD22, Gerasimos Pangalis, MD111, Irina Panovska112*, Viola Maria Popov, MD, PhD, MSc113, Šárka Pospíšilová114*, Lukas Smolej115, Paolo Sportoletti, MD116*, Niki Stavroyianni117*, Constantine S. Tam, MBBS118, Livio Trentin, MD119, Marek Trněný, MD120, Francesc Bosch Albareda121*, Michael Doubek, MD, PhD122,123, Anastasia Chatzidimitriou8*, Paolo Ghia, MD, PhD124,125 and Kostas Stamatopoulos8,126

1Hematology Department and HCT Unit, George Papanicolaou Hospital, Thessaloniki, GRC
2Università Vita-Salute San Raffaele and IRCCS San Raffaele Scientific Institute, Milan, Italy
3Hematology Department and HCT Unit, George Papanikolaou General Hospital, Thessaloniki, Greece
4Masaryk University, Central European Institute of Technology, Brno, Czech Republic
5Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain
6Institute of Applied Biosciences, Center For Research and Technology, Hellas, Thessaloniki, GRC
7Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece, Thessaloniki, Greece
8Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece
9Strategic Research Program on CLL, IRCCS Ospedale San Raffaele, Milano, Italy
10Hematology Department, Hospital Clínico Universitario Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Center of Salamanca-IBMCC (USAL-CSIC), Salamanca, Salamanca, Spain
11Mansoura University, Mansoura, Egypt, Mansoura, Egypt
12Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy
13AF Bone Marrow Transplant Centre/NIBMT, Rawalpindi, Pakistan
14Institut Paoli Calmettes, Marseille, France
15Department of Hematology, Institut Paoli-Calmettes, Marseille, France
16U.O.C. Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
17AHEPA University Hospital, Thessaloniki, Greece
18Royal Bournemouth Hospital, Bournemouth, United Kingdom
19Department of Internal Medicine, Medical Center Augsburg, Augsburg, Germany
20Hospital General Universitario, Valencia, ESP
21Universidades Federal do Espirito Santo, Vitória, Brazil
22First Propedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
23Belfast City Hospital, Belfast, IRL
24Hospital de Clínicas Dr. Manuel Quintela, Montevideo, Uruguay
25University Hospital Center, Zagreb, Croatia
26Iatriko Medical Center, Athens, Greece
27Hospital Italiano La Plata, La Plata, Argentina
28Hematology Institute, Fondazione Policlinico Universitario Agostino Gemelli IRCSS, Roma, Italy
29Department of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy
30Department of Hematology, Hospital General Universitario, Valencia, Spain
31Department of Hematology, Hospital Universitario Infanta Leonor, Madrid, Spain
32Department of Medicine, Division of Hematology and Clinical Immunology, University of Perugia, Perugia, Italy
33Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
34Department of Haematology, University Hospital of Ioannina, Ioannina, Greece
35Department of Hematology, Sourasky Tel Aviv Medical Center, Tel Aviv, Israel
36Dubrava University Hospital, Zagreb, Croatia
37Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
38Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wrocław, Poland
39Department of Hematology, Muğla Sıtkı Koçman University, Muğla, Turkey
40Amsterdam UMC, Amsterdam, NH, Netherlands
41Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong
42Department of Haematology,, University of Athens, Laikon General Hospita, Athens, Greece
43Laboratoire hématologie, APHP Hopital Saint Antoine, Paris, France
44Shamir Medical Center, Zerifin, Israel
45Tel Aviv University, Tel Aviv, Israel
46Democritus University of Thrace, University hospital of Alexandroupolis, Department of Hematology, Alexandroupolis, Greece
47Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, MD
48Department of Medical Oncology Hematology, All India Institute of Medical Sciences (AIIMS), Rishikesh, Rishikesh, India
49Hematology Department, Research Unit, Hospital Universitario de Burgos, Burgos, Spain
50Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
51Department of Hematology, CH Le Mans, Le Mans, France
52Bnai Zion Medical center, Haifa, Israel
53Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain
54Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, 28012, Spain
55University Hospital Brno, Brno, Czech Republic
56La Princesa University Hospital, Madrid, Spain
57Service Hématologie et Oncologie, Hôpital André Mignot, Le Chesnay, France
58Clinic for hematology, Clinical Center of Serbia, Belgrade, Serbia
59University of Belgrade, Belgrade, Serbia
60University of Novi Sad, Novi Sad, Serbia
61University Hospital Doce De Octubre, Madrid, Spain
62Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy
63Medical University of Lublin, Lublin, Poland
64Department of Hematology, St. John's Cancer Center, Lublin, Poland
65University Hospital of Salamanca (HUS/IBSAL), CIBERONC Salamanca, Salamanca, Spain
66Clinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi", Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
67Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic
68First Department of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
69Amsterdam Medical Center, Amsterdam, Netherlands
70Laboratori de Citologia Hematològica i Citogenètica, Servei de Patologia, Hospital del Mar. GRETNHE- Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Spain
71Hematology, St. Anna University Hospital, Cona, Ferrara, Italy
72Department of Hematology, Shaare-Zedek Medical Center, affiliated with the Hebrew University Medical School, Jerusalem, Israel
73Department of Hematology, Medipol University School of Medicine, Istanbul, Turkey
74Kolling Institute of Medical Research, Northern Blood Research Centre, St Leonards, NSW, Australia
75Department of Internal Medicine - Haematology, University Hospital and Medical School, Hradec Kralove, Czech Republic
76National Research Center for Hematology, Moscow, Russian Federation
77Department of Laboratory Medicine and Pathology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
78Charles University, Prague, Czech Republic
79Hematology and Oncology, Medical Faculty, University of Augsburg, Augsburg, Germany
80Hematology Unit, Bnai Zion Medical Center, Haifa, Israel
81Shaare Zedek Medical Center, Jerusalem, Israel
82Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong
83Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy
84Clinical Center of Serbia, Belgrade, Serbia
85Department of Hematology, Maastricht University Medical Center, Maastricht, Netherlands
86Department of Haematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
87University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, and Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, TX, Italy
88Department of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece
89Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Department of Hematology, Union Hospital of Fujian Medical University, Fuzhou, Fujian, China
90Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
91Gazi Universitesi Tip Fakultesi Hastanesi, Besevler, Turkey
92Hematology Oncology Department, National Centre For Cancer Care & Research, Doha, Qatar
93Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
94Department of Hematology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
95Clinical Center Serbia, Belgrade, Serbia
96The molecular hematology laboratory, National Research Center for Hematology, Moscow, Russia
97Haematology Department, Belfast Health and Social Care Trust, Belfast, United Kingdom
98Department of Molecular Biotechnology and Health Sciences and Division of Hematology, University of Torino, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy
99Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
100Hematology Section, St. Anna University Hospital, Ferrara, Italy
101Department of Hematology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey
102Pathology Department, Hospital del Mar, Barcelona, Spain
103Hospital del Mar, Barcelona, Spain
104Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
105Université Clermont-Ferrand, Clermont-Ferrand, France
106Federal State Budgetary Educational Institution of Higher Education Academician I.P., Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation, St. Petersburg, RUS
107Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
10863Royal North Shore Hospital and University of Sydney, Sydney, Australia
109SC Ematologia e CTMO, Ospedale Oncologico A. Businco, ARNAS “G. Brotzu”, Cagliari, CAGLIARI, Italy
110Outpatient Hematology Department, S.P.Botkin City Hospital, Moscow, Russia
111Athens Medical Center, Athens, Greece
112University Clinic for hematology, Skopje, Macedonia, The former Yugoslav Republic of
113Hematology, Colentina Clinical Hospital, Bucharest, Arges, Romania
114CEITEC, Brno, CZE
115Fourth Department of Internal Medicine - Hematology, Charles University, University Hospital and Faculty of Medicine, Prague, Czech Republic
116Centro di Ricerche Emato-Oncologiche, Perugia, Italy
117Hematology Department – HCT Unit, George Papanicolaou Hospital, Thessaloniki, Greece
118Peter MacCallum Cancer Centre, Kew, VIC, Australia
119Hematology and Clinical Immunology Unit, Department of Medicine-DIMED, University of Padua, Padua, Italy
120Charles University, General Hospital, Prague, Czech Republic
121University Hospital Vall d'Hebron, Barcelona, ESP
122Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
123Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Brno, Czech Republic
124Universita' Vita-Salute San Raffaele C.F. 97187560152, Milano, MI, Italy
125European Research Initiative on CLL - ERIC, Barcelona, Spain
126European Research Initiative on CLL, Barcelona, Spain

The use of novel small molecule inhibitors alone or in combination with anti-CD20 monoclonal antibodies for chronic lymphocytic leukemia (CLL) has raised a number of questions on efficacy, tolerability, long-term treatment adherence in patients with heterogeneous clinical features. To fill this gap, we designed a study focusing on treatment sequencing in patients with CLL in order to (i) compare the outcome of patients treated with chemoimmunotherapy (CIT) combinations in first-line versus those receiving Bruton’s tyrosine kinase inhibitors (BTKi); (ii) characterize the efficacy and tolerability of venetoclax-based regimens; (ii) understand the impact of treatment sequencing when it comes to chemo-free options including venetoclax after BTKi and vice versa. Data from consecutive sets of patients diagnosed with CLL between 2000-2020 attended at 77 institutions affiliated with ERIC were collected and analyzed. Collected variables included: demographics, clinical stage at diagnosis, IGHV gene somatic hypermutation status; cytogenetic status for chromosomes 11q, 13q 17p and 12 determined by fluorescence in situ hybridization; TP53 gene mutation status; treatment; treatment response; discontinuation; reason for discontinuation; death. We included 9173 patients with a diagnosis of CLL who received at least one line of treatment. The median age at diagnosis was 67 years with a male:female ratio of 1.9. The median follow-up was 78 months (IQR, 48-120 months). Regarding novel targeted agents, 1860/9173 (20.2%) patients had received at least one line of treatment with BTKi (ibrutinib, n=1788; acalabrutinib, n=72) over the disease course; 631/9173 (6.9%) with venetoclax; and, 447/9173 (4.9%) with the PI3K inhibitor idelalisib. Seventy-nine patients were treated with both BTKi and venetoclax (59 BTKi followed by BCL2i, 20 vice versa). At last follow-up, 5870/9173 patients (64.0%) were alive, 3229/9173 (35.2%) died and 74/9173 (0.8%) were lost to follow-up. Patients treated with BTKi in first-line were enriched for TP53 aberrations [del(17p) 27.6%, TP53 mutation 26.3%] and unmutated IGHV genes (69%) and obtained an ORR of 87.7%. Of these, 136 (26.3%) discontinued treatment after a median of 1.2 years (0.07-5.98); main reasons of discontinuation were toxicity (40.5%) and failure (26.2%). Among 631 patients treated with venetoclax at any line, 100 (15.8%) received BCL2 +/- anti-CD20 as first-line; 170 (26.9%) as second line (125 previously treated with CIT, 27 with BTKi); and, 361 as third or subsequent line. ORR ranged between 71.5% (≥3 lines) with 30.5% CR/CRi to 90.3% (first-line) with 68.1% CR/CRi. Treatment discontinuation was due to toxicity in 28.6% of patients treated in the first-line, and 17.6% and 21.8% of patients treated in second and third-or-higher-line, respectively. Disease progression led to treatment discontinuation in 14.3%, 20.6% and 33.6% in first, second and third-or-higher line, respectively. CIT was used as front-line treatment in 5465 patients (59.6%). Of these, 2070 (37.9%) and 1018 (18.6%) patients received a second and third line of treatment, respectively. The great majority (865/1086 cases, 79.7%) of patients who received a second line before 2014 were retreated with CIT, most commonly Bendamustine-Rituximab (284/1086, 26.1%) and Fludarabine-Cyclophosphamide-Rituximab (252/1086, 23.2%); alemtuzumab monotherapy was used in 55/1086 (5%) of patients. After 2014, 415/984 patients (42.1%) were retreated with BTKi; 93 (9.5%) with venetoclax; 70 (7.2%) with idelalisib; 50 (5%) with Alemtuzumab monotherapy, and 315 (32%) with CIT. Similarly, in the third-or-higher line of treatment, most patients (86.3%) were retreated with CIT before 2014, while BTKi, BCL2i, and PI3Ki were mainly used after 2014 (in 43.1%, 15.7% and 14.7% of cases, respectively). Finally, our cohort included 1075 patients with TP53 aberrations. The ORR of patients receiving BTKis (n=171) as first-line of treatment was 86.5% (22.2 CR+64.3 PR), while the ORR with venetoclax +/- anti-CD20 (n=15) was 91% (45.5% CR+45.5 PR). Patients treated with CIT (n=694) had an ORR of 68.7% (28.3% CR+40.4% PR). In conclusion, in a large international study we provide real world data regarding the selection and sequencing of treatment in CLL, charting a major shift in treatment patterns before and after the introduction of novel trargeted agents and confirming their efficacy even in high-risk CLL.

Disclosures: Scarfo: Janssen: Honoraria, Other: Travel grants; Astra Zeneca: Honoraria; Abbvie: Honoraria. Iacoboni: BMS/Celgene, Gilead, Novartis, Janssen, Roche: Honoraria. Collado: Abbvie,: Other: pharmaceutical Company, Research Funding; Janssen: Other: Pharmaceutical Company, Research Funding. Galimberti: AbbVie, Janssen: Honoraria, Other: Travel grants; Incyte: Speakers Bureau. García-Serra: AbbVie: Other: Educational grands; Janssen: Other: Educational grants; Novartis: Other: Educational grants. Gozzetti: Janssen: Honoraria; AbbVie: Honoraria. Hatzimichael: Amgen, Roche, Genesis, Novartis, Bristol Mayer Squibb, Celgene, Pfizer: Consultancy; Abbvie, Amgen, Bristol Mayer Squibb, MSD, Gilead, Janssen Cilag, Genesis Pharma, Roche, Takeda: Honoraria. Herishanu: AbbVie: Honoraria, Research Funding; Janssen: Honoraria; Roche: Honoraria; Medison: Honoraria. Jaksic: Roche, Oktal-Pharma/Celtrion, Sandoz: Consultancy, Honoraria. Kater: BMS, Roche/Genentech: Other: Ad Board, , Research Funding; Genmab, LAVA: Other: Ad Board, Steering Committee; Janssen, AstraZeneca: Other: Ad Board, steering committee, Research Funding; Abbvie: Honoraria, Other: Ad Board, Research Funding. Kotsianidis: Astellas: Other: NONE, Research Funding, Speakers Bureau; Genesis: Consultancy, Other: NONE; Janssen Hellas: Consultancy, Other: NONE, Speakers Bureau; Bristol Hellas: Consultancy, Other: NONE, Research Funding, Speakers Bureau; Novartis Hellas: Consultancy, Other: NONE, Research Funding, Speakers Bureau; Abbvie: Consultancy, Other: NONE, Research Funding, Speakers Bureau. Kreitman: NIH: Patents & Royalties: Moxetumomab Pasudotox; Genentech: Research Funding; Teva: Research Funding; AstraZeneca/MedImmune: Research Funding; Innate: Research Funding; GSK/Novartis: Research Funding; Array BioPharma/Pfizer: Research Funding. Laribi: BeiGene: Other: Personal Fees; Jansen: Research Funding; Novartis: Other: Personal Fees, Research Funding; Astellas Phama, Inc.: Other: Personal Fees; AstraZeneca: Other: Personal Fees; Le Mans Hospital: Research Funding; Takeda: Other: Personal Fees, Research Funding; AbbVie: Other: Personal Fees, Research Funding; IQONE: Other: Personal Fees. Lopez-Garcia: Roche: Other: Speaker Honoraria, Travel and accommodation grants; Novonordisk: Other: Speaker Honoraria; Fresenius: Other: Speaker Honoraria; Celgene: Other: Speaker Honoraria; Abbvie: Other: Speaker Honoraria, Advisor, Travel and accommodation grants; Janssen: Other: Speaker Honoraria, Advisor, Travel and accommodation grants, Research Funding. Milosevic: Roche: Honoraria; Abbvie,: Honoraria; Janssen: Honoraria; Sandoz: Honoraria. Reda: Beigene: Consultancy; Astra Zeneca: Consultancy; Abbvie: Consultancy; Janssen: Consultancy. Ruchlemer: AbbVie: Consultancy, Honoraria, Research Funding. Šimkovič: Janssen, Gilead, Roche, AstraZeneca, and AbbVie: Other: consultancy fees, advisory board participation fees, travel grants, and honoraria; University Hospital Hradec Kralove: Current Employment; AbbVie: Consultancy, Current equity holder in publicly-traded company, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; Merck: Current equity holder in publicly-traded company; Eli Lilly: Current equity holder in publicly-traded company; J&J: Current equity holder in publicly-traded company; Gilead: Other: Travel, Accommodations, Expenses. Špaček: AbbVie, AstraZeneca, Gilead, Janssen, and Roche: Honoraria. Tadmor: Janssen: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding. Visentin: Italfarmaco and Gilead: Speakers Bureau. Vassilakopoulos: Pfizer: Research Funding; GlaxoSmithKline: Honoraria, Other: Travel; Dr. Reddy's: Research Funding; Amgen: Honoraria, Research Funding; Novartis: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Integris: Honoraria; Merck: Honoraria, Research Funding; AstraZeneca: Honoraria; Genesis Pharma: Consultancy, Honoraria, Other: Travel; Karyopharm: Research Funding; Roche: Consultancy, Honoraria, Other: Travel; Takeda: Consultancy, Honoraria, Other: Travel, Research Funding. Vitale: Janssen: Honoraria. Yáñez: Gilead-Kite, Janssen, AbbVie, AstraZeneca, Beigene, Roche, Pfizer, Jazz, BMS, and Merck: Other: Advisory board participation fees ; Janssen, AbbVie, AstraZeneca, Gilead-Kite, Roche, Pfizer, and Merck: Speakers Bureau. Antic: AbbVie, Janssen, and Roche: Honoraria. Coscia: Janssen: Honoraria, Other, Research Funding; Gilead: Honoraria; AstraZeneca: Honoraria; AbbVie: Honoraria, Other. Cuneo: AstraZeneca: Consultancy, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau. Gaidano: Beigene: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astrazeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Guièze: Janssen: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria; Astrazeneca: Consultancy, Honoraria. Laurenti: AstraZeneca: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Roche: Honoraria, Research Funding; Gilead: Honoraria; Janssen: Consultancy, Honoraria; BeiGene: Honoraria. Murru: Abbvie: Consultancy, Honoraria, Other: travel and accommodation; Janssen: Consultancy, Honoraria. Nikitin: Janssen: Research Funding; AstraZeneca, Janssen, Abbvie: Speakers Bureau. Sportoletti: AstraZeneca: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Tam: Abbvie: Honoraria; Janssen: Honoraria; Beigene: Honoraria; Loxo: Honoraria; Abbvie: Research Funding; Janssen: Research Funding; Beigene: Research Funding. Trněný: Amgen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; Gilead Sciences: Consultancy, Honoraria, Other: Travel, Accommodations, Expenses; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; MorphoSys: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses; Celgene: Consultancy; 1st Faculty of Medicine, Charles University, General Hospital in Prague: Current Employment; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Portola: Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Honoraria; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses. Bosch Albareda: Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Gilead: Consultancy, Honoraria; Abbvie: Consultancy; AstraZeneca: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau; Takeda: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Kite: Honoraria; Sanofi: Honoraria; Lilly: Honoraria. Doubek: Janssen-Cilag, AbbVie, AstraZeneca, Amgen, Gilead, Novartis: Honoraria, Research Funding. Chatzidimitriou: Janssen: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding. Ghia: Roche: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Research Funding; Celgene/Juno/BMS: Consultancy, Honoraria; BeiGene: Consultancy, Honoraria; ArQule/MSD: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; Acerta/AstraZeneca: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Sunesis: Research Funding. Stamatopoulos: AstraZeneca: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Janssen: Honoraria, Research Funding.

*signifies non-member of ASH